benzinga.comIonis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder13 days ago
benzinga.comFDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Diseaseabout 2 months ago
businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7 months ago
businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)8 months ago
businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)8 months ago
businesswire.comKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update9 months ago
businesswire.comKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update9 months ago
businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)9 months ago
businesswire.comKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)9 months ago
CashuKalVista Pharmaceuticals and Ionis Lead Innovation in Hereditary Angioedema Treatment with FDA Approval10 days ago
CashuKalVista Pharmaceuticals Observes Ionis FDA Approval for Innovative HAE Treatment IONS Dawnzera12 days ago
CashuKalVista Pharmaceuticals and the Growing Landscape of HAE Treatments Following Ionis Approval14 days ago